HIV / AIDS in the News

USCHA 2024: Attend an HIV.gov Generative AI and Social Media Lab - POZ

 

HIV services discontinued at Minneapolis housing complex - KSTP

 

Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug - The Wall Street Journal

 

Biden-Harris Administration Issues Proposed Rule to Expand Access to Life-Saving Organs for People with HIV - HIV.gov

 

Gilead Pops After New Shot Blocks 99.9% Of HIV Infections - Investor's Business Daily

 

Nebraska campaign targets HIV awareness with testing and education - KNOP

 

Nebraska campaign targets HIV awareness with testing and education - KNOP

 

An injectable HIV-prevention drug is highly effective — but wildly expensive - NBC News

 

Weld County receives grant for an HIV prevention program - Greeley Tribune

 

Fenway Health Commends PUSPOSE 2 Twice Yearly HIV Pre-Exposure Prophylaxis (PrEP) Injection Study Results - PR Web

 

Gilead’s twice-yearly lenacapavir outperforms Truvada in men - Clinical Trials Arena

 

Twice-Yearly Injection Cuts HIV Risk by 96%, But Will Cost Cut Access? - U.S. News & World Report

 

Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections - Benzinga

 

Francisco Ruiz is bringing his truth to national HIV/AIDS policy - HSPH News

 

Gilead’s (NASDAQ:GILD) Latest Study Shows Further Progress Against HIV - TipRanks

 

Twice-yearly injection reduced HIV infections by 96 percent, company says - The Hill

 

Gilead Stock Rises on Positive Study Results for Twice-Yearly HIV Drug - The Wall Street Journal

 

Triple antibody therapy shows promise for long-lasting HIV control - Medical Xpress

 

National HIV/AIDS Strategy Quality of Life Goals Unlikely to Be Met - AJMC.com Managed Markets Network

 

Creator and host Karl Schmid fights HIV stigma with knowledge - Plus

 

PUBLIC HEALTH CORNER: National HIV/AIDs & Aging Awareness Day - Kirksville Daily Express and Daily News

 

Twice-Yearly Injection Cuts HIV Risk by 96%, But Will Cost Cut Access? - HealthDay

 

Twice-Yearly Injection Cuts HIV Risk by 96%, But Will Cost Cut Access? - Wyoming Tribune

 

With another phase 3 win, Gilead races toward 2025 launch for long-acting PrEP drug - FiercePharma

 

The Critical Role of Transportation in HIV Prevention and Treatment - JPHMP Direct

 

Stigma around those living with HIV is declining, but maybe not for the reasons you'd think: report - Advocate.com

 

Gilead’s HIV Shot Reduced Infections By 96% In Late-Stage Trial—Beating Daily Pill - Forbes

 

Amida Care’s HIV and LGBTQ Clients and Staff Want You to Vote! [VIDEOS] - POZ

 

New Gilead drug reduced HIV infections by 96% in trial - ConsumerAffairs

 

Gilead Stock Jumps After It Unveils More Positive Data on HIV Prevention Shot - Barron's